幽门螺旋杆菌感染治疗现状及CYP2C19基因对抗HP治疗的影响

Current Status of Treatment of Helicobacter Pylori Infection and the Effect of CYP2C19 Gene on HP Treatment

幽门螺旋杆菌(Helicobacter pylori, HP)是螺旋杆菌属的代表菌种,一种革兰阴性微需氧杆菌,它与慢性胃炎、胃十二指肠溃疡、胃腺癌、胃黏膜相关B细胞淋巴瘤(MALT淋巴瘤)发生关系密切。目前波及全球,尤以发展中国家为甚,我国平均感染率高达59%,《H.pylori胃炎京都全球共识》强调H.pylori胃炎是一种感染性疾病,且目前抗HP治疗越来越困难,其中影响因素甚多,以HP耐药率增加尤为突出,但CYP2C19基因多态性对抗幽门螺旋杆菌的影响也逐渐凸显,本文就HP的治疗现状及CYP2C19基因多态性做一综述,旨在对临床医生在治疗幽门螺旋杆菌时有所帮助。

Helicobacter pylori(HP)is a representative strain of Helicobacter,a gram-negative microaerophilic bacterium closely associated with chronic gastritis,gastroduodenal ulcer,gastric adenocarcinoma and gastric mucosaassociated B cell lymphoma(MALT lymphoma).At present,the infection rate is as high as 59%in China,especially in developing countries.The Kyoto global consensus on HPylori gastritis emphasizes that HPylori gastritis is an infectious disease,and anti HP treatment is becoming more and more difficult at present,among which there are many influencing factors,especially the increase of HP resistance rate,but the influence of CYP2C19 gene polymorphism on HP infection is also gradually prominent.This article reviews the current situation of anti-HP treatment and CYP2C19 gene polymorphism,with a view to helping clinicians in treating helicobacter pylori.